Real scenarios. Real coverage.

A mid-sized vendor consortium operates four food and beverage stalls at a major US outdoor music festival, the kind of two-weekend event that draws roughly 75,000 attendees per day. Concessions, merchandise, and VIP hospitality generate millions in ancillary revenue across the run.

During the second weekend of a recent fall edition, steady rain turned the festival grounds into a slippery mud pit. The event was never cancelled. The stages kept running. But by mid-afternoon on Saturday, thousands of attendees who had not come prepared with boots or rain gear had already left or retreated to covered areas. The back half of the grounds, where mid-tier vendor stalls, merchandise tents, and food trucks are concentrated, ran at an estimated 40–50% of normal foot traffic for the bulk of the afternoon.

That's not a cancellation. That's not a hurricane. That's a grey zone, and traditional event insurance doesn't touch it.

The consortium's combined Saturday revenue came in at $114,000 against a dry-day projection of $190,000. A single-day shortfall of $76,000, with no recourse.

In early 2025, the US government imposed a 10% global baseline tariff under the International Emergency Economic Powers Act (IEEPA). For mid-sized importers with supply chains running through China and Southeast Asia, this wasn't an abstraction. It was a non-budgeted cash drain that hit immediately and hit hard.

Then came the court win. The Supreme Court ruled the IEEPA tariffs illegal and ordered a full refund to importers. Across the industry, approximately $166 billion in duties were now owed back to US businesses.

The catch: US Customs and Border Protection declared its systems unsuited for a task of this scale. The agency is currently building new functionality in the Automated Commercial Environment to process 53 million individual entry refunds. The projected timeline runs into months, possibly years.

Companies that fought and won are now what trade coalition members have started calling "paper billionaires," holding a court order they cannot deposit. Meanwhile, the administration has already pivoted to Section 301 and Section 122 duties to replace the invalidated tariffs, meaning the same importers are now paying new duties while waiting for old ones to be refunded.

The only liquidity option on the market: hedge funds and specialty finance firms offering to buy refund rights at 40–50 cents on the dollar. For a company with $4.2M in pending refunds, that means walking away with $2.1M and handing the other half to a fund that will wait out the government's administrative backlog.

A major US television network is producing the live finale of one of its flagship spring entertainment series. Advertising inventory is sold out at approximately $450,000 per 30-second spot across the two-hour broadcast. Production write-offs, contractual penalties, and talent fees in the event of cancellation would push the all-in commercial exposure to roughly $60 million.

90 minutes before air, a video uploaded to social media by a former boyfriend of the season's star shows the lead talent in a domestic altercation. By the time the network's crisis team convenes, the clip has 4 million views. By the time the cancellation decision is made, it has 12 million. Archival programming runs in the 9pm slot.

Standard production insurance covers cast illness, act of god, and venue failure. It does not cover reputational crises triggered by third-party leaks. There is no policy in the world that pays out on this event.

In early 2025, the FDA added injectable semaglutide—the active compound in Ozempic and Wegovy—to its 503B outsourcing shortage list. That administrative designation, quietly maintained in a federal database, unlocked a market. Under US law, when a drug appears on the shortage list, licensed 503B outsourcing facilities may produce compounded versions without the usual restrictions. For cash-pay telehealth platforms prescribing weight-loss medications, this created an opening: branded GLP-1 injections retailing at $900–$1,300 per month could now be prescribed as compounded semaglutide at $150–$250. Demand exploded.

A mid-sized cash-pay telehealth platform built its core business around this window. By early 2025, GLP-1 prescriptions represented $42 million in annualized run-rate revenue—roughly 68% of total platform revenue. The business model was profitable, growing fast, and entirely dependent on a single FDA list entry remaining in place.

In March 2025, the FDA announced that injectable semaglutide shortages had been resolved and initiated the process of removing it from the 503B shortage list. When the removal was finalized, 503B facilities would be required to stop compounding. Platforms prescribing compounded versions would lose their legal product. The FDA gave no firm date. The process could take months.

The company's CFO modeled three scenarios: removal in Q3 2025, Q4 2025, or Q1 2026. Under any scenario, the revenue impact in the transition quarter would exceed $10 million. Under the earliest scenario—removal by September—the platform had eight weeks to find substitute revenue or cut costs. There is no insurance policy that covers regulatory timing risk. No carrier in the market will write a bespoke instrument on an FDA administrative decision.